Weekly Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings on May 16, 2018

May 16, 2018 - By Mark Mitchell

Myriad Genetics, Inc. (NASDAQ:MYGN) Corporate Logo
During 2017 Q4 the big money sentiment increased to 1.37. That’s change of 0.51, from 2017Q3’s 0.86. 19 investors sold all, 67 reduced holdings as Myriad Genetics, Inc. ratio improved. 72 increased stakes while 46 funds amassed stakes. Funds hold 71.43 million shares thus 0.51% less from 2017Q3’s 71.79 million shares.
X Ltd Liability reported 0% stake. Rhumbline Advisers owns 162,219 shs. Cornerstone Incorporated holds 0% or 140 shs in its capital. Blackrock invested in 10.07 million shs. Barclays Plc has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Huntington Retail Bank holds 0% or 198 shs. Point72 Asset Lp reported 863,948 shs. Albert D Mason owns 16,432 shs. Prudential Fincl reported 0.01% stake. Jefferies Grp Inc Limited Liability reported 9,619 shs. Bnp Paribas Arbitrage reported 29,509 shs stake. Parsec Inc invested 0.08% of its capital in Myriad Genetics, Inc. (NASDAQ:MYGN). Ghp Advsr Inc holds 50,120 shs or 0.24% of its capital. Canada Pension Plan Inv Board has 550,500 shs for 0.04% of their capital. Louisiana State Employees Retirement Sys holds 0.05% of its capital in Myriad Genetics, Inc. (NASDAQ:MYGN) for 29,800 shs.

Myriad Genetics, Inc. registered $5.48 million net activity with 0 insider buys and 7 selling transactions since December 11, 2017. 7,500 shs valued at $248,925 were sold by GILBERT WALTER PHD on Thursday, December 14. On Monday, January 22 King Gary A. also sold $1.37 million worth of Myriad Genetics, Inc. (NASDAQ:MYGN). DREISMANN HEINRICH sold $201,000 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) on Monday, December 11.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

Total analysts of 8 have positions in Myriad Genetics (NASDAQ:MYGN) as follows: 2 rated it a “Buy”, 1 with “Sell” and 5 with “Hold”. The positive are 25%. Since January 2, 2018 according to StockzIntelligence Inc Myriad Genetics has 12 analyst reports. On Wednesday, May 9 the rating was maintained by Morgan Stanley with “Equal-Weight”. On Wednesday, February 7 BTIG Research maintained Myriad Genetics, Inc. (NASDAQ:MYGN) rating. BTIG Research has “Buy” rating and $44.0 target. In Monday, January 22 report Barclays Capital maintained it with “Hold” rating and $35.0 target. In Tuesday, February 6 report Piper Jaffray maintained it with “Hold” rating and $31.0 target. The stock rating was upgraded by Morgan Stanley to “Equal-Weight” on Wednesday, March 21. The company rating was maintained by Jefferies on Wednesday, February 7. On Wednesday, February 7 Morgan Stanley maintained Myriad Genetics, Inc. (NASDAQ:MYGN) rating. Morgan Stanley has “Underweight” rating and $28 target. On Wednesday, February 7 the rating was maintained by Leerink Swann with “Market Perform”. On Tuesday, January 2 the stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Buy” rating given by Stephens. Listed here are Myriad Genetics, Inc. (NASDAQ:MYGN) PTs and latest ratings.

09/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $33 New Target: $35 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Equal-Weight Old Target: $28 Upgrade
07/02/2018 Broker: BTIG Research Rating: Buy New Target: $44.0 Maintain
07/02/2018 Broker: Jefferies Rating: Hold New Target: $35.0 Maintain
07/02/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $33 New Target: $35 Maintain
07/02/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $26 New Target: $28 Maintain
06/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $31.0 Maintain
29/01/2018 Broker: Goldman Sachs Rating: Sell New Target: $32 Initiates Coverage On
22/01/2018 Broker: Barclays Capital Rating: Hold New Target: $35.0 Maintain
16/01/2018 Broker: BTIG Research Rating: Buy New Target: $41.0

Ticker’s shares touched $34.99 during the last trading session after 3.48% change.Myriad Genetics, Inc. has volume of 393,104 shares. Since May 16, 2017 MYGN has risen 52.68% and is uptrending. MYGN outperformed by 41.13% the S&P 500.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide.The firm is valued at $2.45 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.18.77 is the P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

For more Myriad Genetics, Inc. (NASDAQ:MYGN) news released briefly go to: Globenewswire.com, Businesswire.com, Nasdaq.com, Prnewswire.com or Globenewswire.com. The titles are as follows: “SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100000 From …” released on April 26, 2018, “MYGN EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Myriad …” on May 10, 2018, “Myriad Genetics to Present Five Studies at the Seventh International Symposium on Hereditary Breast and Ovarian …” with a publish date: May 04, 2018, “SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Myriad …” and the last “Kaskela Law LLC: Shareholder Class Action Filed Against Myriad Genetics, Inc. – MYGN” with publication date: May 06, 2018.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: